Mette H Viuff 1,2 , Agnethe Berglund 1,2,3 , Svend Juul 4 , Niels H Andersen 5 , Kirstine Stochholm 2 , Claus H Gravholt 1,2 Show Affiliations »
Abstract
CONTEXT: The long-term effects of female hormone replacement therapy (HRT) in Turner syndrome (TS) are unknown. OBJECTIVE: To examine morbidity, mortality and medicinal use in TS and the impact of HRT in 45,X women. DESIGN AND SETTING: National cohort study, following all TS individuals ever diagnosed in Denmark from 1977 to 2014. PATIENTS AND METHODS: In the Danish Cytogenetic Central Registry, we identified 1,156 females diagnosed with TS during 1960-2014, and subsequently, Statistics Denmark randomly identified 115,577 age-matched female controls. TS women and their matched controls were linked with person-level data from the National Patient Registry and the Medication Statistics Registry, and they were compared concerning mortality, hospitalizations, and medical prescriptions. Among 329 45,X women, 44 had never been HRT treated, and 285 had been treated at some point. HRT treated women were compared with untreated concerning mortality, hospitalizations, and medical prescriptions. RESULTS: Endocrine and cardiovascular mortality and morbidity were significantly increased in TS compared with the matched controls. Comparing HRT treated with non-treated 45,X women, we found a similar mortality; Hazard Ratio 0.83 (95% CI 0.38-1.79). Among the HRT treated 45,X women, we found a significantly lower use of antihypertensives, antidiabetics, and thyroid hormones, and significantly reduced hospitalization rates for stroke and osteoporotic fractures. CONCLUSION: Women with TS have an increased overall mortality and morbidity. HRT seems to have a beneficial effect on endocrine conditions, hypertension, and stroke in women with 45,X karyotype, with no clear impact on mortality. © Endocrine Society 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
CONTEXT: The long-term effects of female hormone replacement therapy (HRT) in Turner syndrome (TS ) are unknown. OBJECTIVE: To examine morbidity, mortality and medicinal use in TS and the impact of HRT in 45,X women . DESIGN AND SETTING: National cohort study, following all TS individuals ever diagnosed in Denmark from 1977 to 2014. PATIENTS AND METHODS: In the Danish Cytogenetic Central Registry, we identified 1,156 females diagnosed with TS during 1960-2014, and subsequently, Statistics Denmark randomly identified 115,577 age-matched female controls. TS women and their matched controls were linked with person -level data from the National Patient Registry and the Medication Statistics Registry, and they were compared concerning mortality, hospitalizations, and medical prescriptions. Among 329 45,X women , 44 had never been HRT treated, and 285 had been treated at some point. HRT treated women were compared with untreated concerning mortality, hospitalizations, and medical prescriptions. RESULTS: Endocrine and cardiovascular mortality and morbidity were significantly increased in TS compared with the matched controls. Comparing HRT treated with non-treated 45,X women , we found a similar mortality; Hazard Ratio 0.83 (95% CI 0.38-1.79). Among the HRT treated 45,X women , we found a significantly lower use of antihypertensives, antidiabetics, and thyroid hormones, and significantly reduced hospitalization rates for stroke and osteoporotic fractures . CONCLUSION: Women with TS have an increased overall mortality and morbidity. HRT seems to have a beneficial effect on endocrine conditions, hypertension , and stroke in women with 45,X karyotype, with no clear impact on mortality. © Endocrine Society 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Entities: Disease
Species
Year: 2019
PMID： 31545360 DOI： 10.1210/clinem/dgz039
Source DB: PubMed Journal: J Clin Endocrinol Metab ISSN： 0021-972X Impact factor: 5.958